Center of Drug Absorption and Transport, Department of Clinical Pharmacology, Felix-Hausdorff-Str. 3, University Medicine Greifswald, D-17487 Greifswald, Germany.
Pharmacol Ther. 2019 Mar;195:39-53. doi: 10.1016/j.pharmthera.2018.10.007. Epub 2018 Oct 19.
Intestinal transporter proteins, along with drug metabolizing enzymes, play a major role in the disposition of orally administered drugs, nutrients and xenobiotics. In this regard, efflux transporters such as ABCB1 and ABCG2 can limit oral bioavailability, while uptake carriers such as PEPT1 have the potential to facilitate intestinal absorption. In contrast to the extensive information on intestinal efflux pumps, detailed knowledge about the respective uptake carriers is rather limited. During the last decade, organic anion transporting polypeptide (OATP) transporters have been frequently discussed as clinically relevant uptake transporters for endogenous compounds as well as drugs. Many drug-drug interactions or food-drug interactions that have been observed have been attributed to inhibition of intestinal OATPs. Moreover, an OATP-mediated drug delivery approach assumes OATPs to be target for improving oral drug absorption. However, recent data from several research groups question the established paradigm of intestinal OATPs as uptake carriers. This review aims to provide a comprehensive up-to-date overview regarding the expression, localization and function of OATP transporters in the human intestine.
肠转运蛋白与药物代谢酶一起,在口服药物、营养素和外源性物质的处置中起着重要作用。在这方面,外排转运蛋白如 ABCB1 和 ABCG2 可以限制口服生物利用度,而摄取载体如 PEPT1 则有可能促进肠道吸收。与广泛的肠外排泵信息相比,关于各自摄取载体的详细知识相当有限。在过去的十年中,有机阴离子转运多肽 (OATP) 转运蛋白经常被讨论为内源性化合物和药物的临床相关摄取转运蛋白。已经观察到的许多药物-药物相互作用或食物-药物相互作用归因于肠 OATPs 的抑制。此外,OATP 介导的药物递送方法假定 OATPs 是改善口服药物吸收的靶标。然而,来自几个研究小组的最新数据对肠道 OATPs 作为摄取载体的既定模式提出了质疑。本综述旨在提供有关 OATP 转运蛋白在人肠中的表达、定位和功能的全面最新概述。